Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Research Tools and Instruments

University of Calgary

$145,393.00

Modeling Alzheimer's disease on-chip using microfluidic and tissue engineering approaches

FY 2017-18

Summary
Alzheimer's Disease (AD) is a progressive neurodegenerative disease associated with cognitive dysfunction in the brain. An estimated 500,000 Canadian have AD, including 70,000 age 65 years. The main cause of AD has not been clearly discovered, and therefore the effective treatment to stop the disease or reverse its progression has not yet been established. It is mainly believed that a group of soluble folded proteins like Amyloid beta (A) aggregates to insoluble forms in the brain where they play an essential role in neuronal degeneration functions. A in AD patients can impair synaptic function extracellularly via the direct deposition on synapses or intracellularly through interrupting the axonal transmission. The existing models are not able to determine the contribution of any of these two ways in synaptic dysfunction due to inability in local delivery of molecules into specific cellular compartments. Microfluidics, in particular, has the capability for spatiotemporal delivery of molecules to the synaptic site. The overall objective of the proposed work is to understand how extracellular A peptides spatiotemporally delivered to synapses contribute in dysfunction of synapses and pathology of AD. This is instrumental for the design of specific agents blocking the toxic effect of this polypeptide in AD brain. To unravel the mechanisms underlying the effect of ECM-based A on synaptic dysfunction, it is essential to analyze the spatiotemporal delivery of molecules to synapses in real-time, and at the same time determine how ECM-based A interacts with synapses and axons. The funding provided by this project will enable the purchase of an Olympus IX83 inverted fluorescent microscope with the capability of live-cell imaging, an instrument that can investigate the interaction of misfolded proteins with neurons in real-time. Using the real-time characterizing both spatiotemporal delivery of A to synapses and the interaction of ECM-based A with synapses and axons, we can exceptionally determine the contribution of any of 1) direct deposition of ECM-based A at synapses, 2) disruption in fluxes at post-synaptic and pre-synaptic sites, and 3) interruption in axonal transmission, on failure in synaptic activity, important in pathology of AD. It will also help to determine the type and threshold concentration of ECM-based A that impairs synaptic plasticity with the application in the identification of cell surface receptors and signaling pathways mediating A-induced toxicity.
Program
Research Tools and Instruments
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
RTI-2017-00227
Name nom
SanatiNezhad, Amir
Department département
Mechanical and Manufacturing Engineering - Mechanical and Manufacturing Engineer
Organization id
11
Institution établissement
University of Calgary
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
145393
Program id
RTI
Program name en
Research Tools and Instruments
Program name fr
Outils et instruments de recherche
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1609
Committee name en
Engineering (RTI)
Committee name fr
Génie (OIR)
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Partie
2
Nb partie
2
Application title
Modeling Alzheimer's disease on-chip using microfluidic and tissue engineering approaches
Keyword
NSERC
Application summary
Alzheimer's Disease (AD) is a progressive neurodegenerative disease associated with cognitive dysfunction in the brain. An estimated 500,000 Canadian have AD, including 70,000 age 65 years. The main cause of AD has not been clearly discovered, and therefore the effective treatment to stop the disease or reverse its progression has not yet been established. It is mainly believed that a group of soluble folded proteins like Amyloid beta (A) aggregates to insoluble forms in the brain where they play an essential role in neuronal degeneration functions. A in AD patients can impair synaptic function extracellularly via the direct deposition on synapses or intracellularly through interrupting the axonal transmission. The existing models are not able to determine the contribution of any of these two ways in synaptic dysfunction due to inability in local delivery of molecules into specific cellular compartments. Microfluidics, in particular, has the capability for spatiotemporal delivery of molecules to the synaptic site. The overall objective of the proposed work is to understand how extracellular A peptides spatiotemporally delivered to synapses contribute in dysfunction of synapses and pathology of AD. This is instrumental for the design of specific agents blocking the toxic effect of this polypeptide in AD brain. To unravel the mechanisms underlying the effect of ECM-based A on synaptic dysfunction, it is essential to analyze the spatiotemporal delivery of molecules to synapses in real-time, and at the same time determine how ECM-based A interacts with synapses and axons. The funding provided by this project will enable the purchase of an Olympus IX83 inverted fluorescent microscope with the capability of live-cell imaging, an instrument that can investigate the interaction of misfolded proteins with neurons in real-time. Using the real-time characterizing both spatiotemporal delivery of A to synapses and the interaction of ECM-based A with synapses and axons, we can exceptionally determine the contribution of any of 1) direct deposition of ECM-based A at synapses, 2) disruption in fluxes at post-synaptic and pre-synaptic sites, and 3) interruption in axonal transmission, on failure in synaptic activity, important in pathology of AD. It will also help to determine the type and threshold concentration of ECM-based A that impairs synaptic plasticity with the application in the identification of cell surface receptors and signaling pathways mediating A-induced toxicity.